Review
Medicine, General & Internal
Shinji Okabayashi, Hajime Yamazaki, Ryohei Yamamoto, Keisuke Anan, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Yusuke Honzawa, Yuki Kataoka, Yasushi Tsujimoto, Norio Watanabe
Summary: CZP probably results in a large reduction in failure to maintain clinical remission and response at week 26 in people with CD. The evidence suggests that CZP may lead to no difference in serious adverse events compared to placebo when used as a remission maintenance treatment.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Dermatology
Meltem Turkmen, Sinan Dogan
Summary: The study demonstrated that Certolizumab pegol is an effective and safe therapeutic option for patients with moderate-to-severe chronic plaque psoriasis. CZP led to significant reductions in PASI, PGA, and cDAPSA scores at week 4 of treatment. No adverse effects were observed during CZP treatment, even during the COVID-19 pandemic.
DERMATOLOGIC THERAPY
(2021)
Article
Immunology
Pablo Coto-Segura, Cristina Segu-Verges, Antonio Martorell, David Moreno-Ramirez, Guillem Jorba, Valentin Junet, Filippo Guerri, Xavier Daura, Baldomero Oliva, Carlos Cara, Olaya Suarez-Magdalena, Sonya Abraham, Jose Manuel Mas
Summary: This study used computational modeling to investigate the response variability of moderate-to-severe psoriasis patients to CZP treatment. By generating virtual populations and simulating different dosing regimens, the researchers identified drug efficacy differences in diverse subpopulations and revealed mechanisms of action for different dosing schemes.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Pavine L. C. Lefevre, Parambir S. Dulai, Zhongya Wang, Leonardo Guizzetti, Brian G. Feagan, Anca Pop, Mohamed Yassine, Lisa M. Shackelton, Vipul Jairath, William J. Sandborn, Niels Vande Casteele
Summary: Certolizumab pegol (CZP) is effective for Crohn's disease, with higher plasma concentrations linked to better outcomes and increased drug clearance driving suboptimal concentrations. A prediction model incorporating CZP clearance and patient variables can estimate the probability of remission prior to therapy initiation. Patient-level probabilities for composite remission outcomes can be predicted using online clinical decision support tools by entering common patient- and disease-related factors.
Article
Multidisciplinary Sciences
Ian R. White, Sarah E. Kleinstein, Christophe Praet, Chris Chamberlain, Duncan McHale, Jessica M. Maia, Pingxing Xie, David B. Goldstein, Thomas J. Urban, Patrick R. Shea
Summary: This study aimed to identify genetic variants predictive of CZP response, but did not find a clear predictor of CZP response.
Article
Rheumatology
Xenofon Baraliakos, Sebastian Kruse, Simone E. Auteri, Natasha de Peyrecave, Tommi Nurminen, Thomas Kumke, Bengt Hoepken, Juergen Braun
Summary: Fat lesions on MRI T1 sequences are early indicators of structural spinal progression in patients with axial spondyloarthritis (axSpA). This study analyzed the impact of tumor necrosis factor inhibitor (TNFi) treatment over 4 years on fat lesions in spinal vertebral edges of axSpA patients.
Article
Immunology
Nils Venhoff, Jens Thiel, Markus A. Schramm, Ilona Jandova, Reinhard E. Voll, Cornelia Glaser
Summary: Limited treatment options are available for pregnant patients with Cogan's syndrome due to potential fetal toxicity. Certolizumab pegol is considered safe for pregnant patients with underlying inflammatory diseases, but there is currently a lack of literature on its use in Cogan's syndrome patients, especially during pregnancy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Paul Manka, Svenja Sydor, Nishikant Wase, Jan Best, Malte Brandenburg, Annika Hellbeck, Julia Schanzer, Ramiro Vilchez-Vargas, Alexander Link, Anja Figge, Andreas Jahnert, Ulrike von Arnim, Jason D. Coombes, Francisco-Javier Cubero, Alisan Kahraman, Moon-Sung Kim, Julia Kalsch, Sonja Kinner, Klaas-Nico Faber, Han Moshage, Guido Gerken, Wing-Kin Syn, Scott L. Friedman, Ali Canbay, Lars P. Bechmann
Summary: In this study, the potential relationship between anti-TNF treatment and hepatic steatosis in Crohn's disease was analyzed. Patients on anti-TNF treatment showed reduced hepatic steatosis, higher serum FGF19 levels, and lower levels of neutral lipids such as triglycerides. The abundance of Firmicutes, bacteria involved in bile acid metabolism and FGF19 regulation, was associated with triglyceride levels and showed group-specific alterations.
LIVER INTERNATIONAL
(2021)
Article
Immunology
Liliana Lykowska-Szuber, Michal Walczak, Marzena Skrzypczak-Zielinska, Joanna Suszynska-Zajczyk, Kamila Stawczyk-Eder, Katarzyna Waszak, Piotr Eder, Anna Wozniak, Iwona Krela-Kazmierczak, Ryszard Slomski, Agnieszka Dobrowolska
Summary: Crohn's disease patients who do not respond to anti-TNF therapy may have alterations in the expression levels of specific genes, particularly TNFRSF1B, FCGR3A, and IL1B. This can be predicted by functional analysis in colon biopsies and cell culture models.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Albert Boronat-Toscano, Diandra Monfort-Ferre, Margarita Menacho, Aleidis Caro, Ramon Bosch, Beatriz Espina, Francisco Algaba-Chueca, Alfonso Saera-Vila, Alicia Moline, Marc Marti, Eloy Espin, Monica Millan, Carolina Serena
Summary: This study found that anti-TNF therapy can restore the morphology of creeping fat in patients with CD, suppress immune cell infiltration, and improve inflammation in adipose tissue.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Gastroenterology & Hepatology
Renske W. M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Maria J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamas Molnar, Kata Szanto, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D'Haens, Annemarie C. de Vries
Summary: This study validated and updated a prediction model for relapse risk stratification in Crohn's disease (CD) patients after anti-TNF therapy cessation. The updated model, including clinical symptoms at cessation, younger age at diagnosis, no concomitant immunosuppressants, smoking, second-line anti-TNF therapy, upper gastrointestinal tract involvement, adalimumab, age at cessation, C-reactive protein, and longer disease duration, showed a reasonable discriminative ability (C-statistic, 0.59). Adding fecal calprotectin improved the model's discriminative ability (C-statistic, 0.63). Further validation is necessary, but this model may be useful in guiding clinical decisions on anti-TNF therapy cessation in CD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Rheumatology
Irene E. van der Horst-bruinsma, Philip C. Robinson, Ennio G. Favalli, Frank D. Verbraak, Mindy Kim, Thomas Kumke, Lars Bauer, Bengt Hoepken, Atul Deodhar
Summary: The study compiled data on the impact of CZP on axSpA-associated AAU patients, showing that CZP is effective in reducing AAU flares and there were no differences in outcomes among different axSpA subgroups, age or sex.
RHEUMATOLOGY AND THERAPY
(2022)
Article
Gastroenterology & Hepatology
Simeng Lin, Eilis Hannon, Mark Reppell, Jeffrey F. Waring, Nizar Smaoui, Valerie Pivorunas, Heath Guay, Neil Chanchlani, Claire Bewshea, Benjamin Y. H. Bai, Nicholas A. Kennedy, James R. Goodhand, Jonathan Mill, Tariq Ahmad, PANTS Consortium
Summary: The study identified epigenetic biomarkers in whole blood at baseline that can predict anti-TNF drug concentrations at week 14, which may help identify patients who could benefit from dose optimization at the beginning of anti-TNF therapy.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Rheumatology
Walter P. Maksymowych, Thomas Kumke, Simone E. Auteri, Bengt Hoepken, Lars Bauer, Martin Rudwaleit
Summary: In non-radiographic axial spondyloarthritis (nr-axSpA) patients, younger age and male sex are predictors of clinical response at Week 12 in patients treated with certolizumab pegol (CZP). For long-term clinical response at Week 52, sacroiliitis on MRI and HLA-B27 positivity are consistent predictors across multiple efficacy outcomes in CZP-treated patients.
ARTHRITIS RESEARCH & THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Rosario Medina-Medina, Eva Iglesias-Flores, Jose M. Benitez, Sandra Marin-Pedrosa, Isabel Salgueiro-Rodriguez, Clara I. Linares, Sandra Gonzalez-Rubio, Pilar Soto-Escribano, Beatriz Gros, Manuel L. Rodriguez-Peralvarez, Jose L. Cabriada, Maria Chaparro, Javier P. Gisbert, Eduardo Chicano-Galvez, Ignacio Ortea, Gustavo Ferrin, Valle Garcia-Sanchez, Patricia Aguilar-Melero
Summary: Therapy with anti-TNF has transformed the treatment of Crohn's disease, but long-term efficacy is limited and adverse events can occur. This study aimed to find reliable markers to predict response to anti-TNF drugs in Crohn's disease patients. By comparing protein expression profiles in plasma samples, we identified 18 differentially expressed proteins, including vinculin, that may serve as biomarkers for short-term remission. Plasma vinculin levels, along with other factors such as baseline CD Activity Index, corticosteroid induction, and bowel resection, can predict non-short-term remission.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Gastroenterology & Hepatology
Nathalie Van Den Berghe, Bram Verstockt, Severine Vermeire, Debby Thomas, Paul Declerck
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Kevin L. Winthrop, Severine Vermeire, Millie D. Long, Julian Panes, Siew C. Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y. Melmed
Summary: The incidence rates of herpes zoster in patients with ulcerative colitis remained stable during 7.8 years of tofacitinib exposure. Older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor failure were identified as significant risk factors for herpes zoster.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire
Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Edward Loftus, Peter D. R. Higgins, James O. Lindsay, Wen Zhou, Xuan Yao, Dapo Ilo, Charles Phillips, Jacinda Tran, Yuri Sanchez Gonzalez, Severine Vermeire
Summary: The study evaluated the benefits of UPA on the HRQoL of patients with ulcerative colitis, and found that UPA treatment significantly improved patients' quality of life.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Dotan Yogev, Bram Verstockt, Axel Dignass, Gili Focht, Ohad Atia, Iris Dotan, Severine Vermeire, Dan Turner
Summary: Evaluation of the modified version of the Mucosal Inflammation Noninvasive Index in adult Crohn's disease.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Gary R. Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T. Judd, Thomas Jones, Edward V. Loftus
Summary: Age is considered a risk factor for adverse events in the tofacitinib ulcerative colitis clinical program, with older individuals potentially having a higher risk of herpes zoster, malignancies (excluding nonmelanoma skin cancer), and nonmelanoma skin cancer compared to younger patients.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Sara Deleu, Kaline Arnauts, Lowie Deprez, Kathleen Machiels, Marc Ferrante, Geert R. B. Huys, Johan M. M. Thevelein, Jeroen Raes, Severine Vermeire
Summary: Short-chain fatty acids and their bacterial producers are gaining increasing attention in inflammatory bowel diseases. Acetate, although less studied compared to butyrate, shows potential in being less toxic to epithelial cells, stimulating butyrate-producing bacteria, and having anti-inflammatory and barrier-protective properties. In a study using organoid-based monolayer cultures from ulcerative colitis patients, high acetate concentrations were found to improve epithelial resistance, decrease pro-inflammatory markers, and enhance barrier gene expression. These findings suggest that acetate may offer a promising approach for managing barrier defects and inflammation in IBD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Wannee Kantasiripitak, Sebastian G. Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Severine Vermeire, Karen van Hoeve, Erwin Dreesen
Summary: The study aimed to develop a multi-model model-based software tool for guiding personalized infliximab induction treatment in pediatric inflammatory bowel disease patients. The study found that using the tool for individualized dosing improved the chances for children to achieve deep remission at 6 months.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Loris Riccardo Lopetuso, Sara Deleu, Lihi Godny, Valentina Petito, Pierluigi Puca, Federica Facciotti, Harry Sokol, Gianluca Ianiro, Luca Masucci, Maria Abreu, Iris Dotan, Samuel Paul Costello, Ailsa Hart, Tariq H. Iqbal, Sudarshan Paramsothy, Maurizio Sanguinetti, Silvio Danese, Herbert Tilg, Fabio Cominelli, Theresa T. Pizarro, Alessandro Armuzzi, Giovanni Cammarota, Antonio Gasbarrini, Severine Vermeire, Franco Scaldaferri
Summary: An international panel of experts has generated evidence-based guidelines for the evaluation and management of inflammatory bowel disease (IBD) using faecal microbiota transplantation (FMT). The guidelines provide specific statements and recommendations to promote FMT as a recognized strategy for the treatment of IBD.
Letter
Gastroenterology & Hepatology
Bram Verstockt, Maaike Vancamelbeke, Severine Vermeire
Article
Gastroenterology & Hepatology
Gabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, Albert Wolthuis, Marc Ferrante, Gert de Hertogh, Severine Vermeire, Andre D'Hoore
Summary: The macroscopic appearance of the bowel and associated mesentery during surgery does not appear to be predictive of postoperative recurrence after ileocecal resection for Crohn's disease. Prospective studies investigating risk factors for Crohn's disease recurrence after surgery are scarce.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro
Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Marla C. Dubinsky, David B. Clemow, Theresa Hunter Gibble, Xingyuan Li, Severine Vermeire, Tadakazu Hisamatsu, Simon P. L. Travis
Summary: This study analyzed the efficacy of Mirikizumab in reducing bowel urgency in ulcerative colitis patients, and found that the drug is effective in improving this symptom and is associated with other clinical outcomes.
CROHNS & COLITIS 360
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Loewenberg, Daniel R. Gaya, Silvio Danese
Summary: The STARDUST LTE study is the first interventional study to investigate the efficacy of ustekinumab in Crohn's disease. The study showed that flexible, algorithm-driven dose adjustment, including dose reduction, preserved clinical and endoscopic outcomes for up to 104 weeks.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Severine Vermeire, Jurij Hanzel, Mark Lowenberg, Marc Ferrante, Peter Bossuyt, Frank Hoentjen, Denis Franchimont, Karoly Palatka, Harald Peeters, Aart Mookhoek, Gert de Hertogh, Tamas Molnar, Wouter van Moerkercke, Triana Lobaton, Esme Clasquin, Melanie S. Hulshoff, Filip Baert, Geert D'Haens
Summary: This study explored the differential efficacy of vedolizumab in early and late ulcerative colitis and evaluated clinical, endoscopic, and histological outcomes. The results showed no significant differences between early and late UC in terms of clinical, endoscopic, and histological improvement.
JOURNAL OF CROHNS & COLITIS
(2023)